Furthermore, the peritoneal cavity is lined by mesothelial cells that do not express EpCAM.20 Therefore, the i.p. administration of catumaxomab offers the advantage of a targeted, locoregional immunotherapy against EpCAM+ tumor cells in the peritoneal cavity, which are the main cause of malignant ascites. The gene discussed is EPCAM; the disease is neoplasm.